multidrug resistant infections
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
EMA’s PRIME scheme launches three major new features
The scheme supports the development of treatments targeting unmet medical needs in the EU
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030
The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China
AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus
Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive